AORT

Company Overview — What Does ARTIVION, INC. Do?

Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia. ARTIVION, INC. (AORT) is classified as a small-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO James P. Mackin and employs approximately 1,300 people, headquartered in KENNESAW, Georgia. With a market capitalization of $1.6B, AORT is one of the notable companies in the Healthcare sector.

ARTIVION, INC. (AORT) Stock Rating — Hold (April 2026)

As of April 2026, ARTIVION, INC. receives a Hold rating with a composite score of 43.7/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.AORT ranks #1,858 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, ARTIVION, INC. ranks #189 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

AORT Stock Price and 52-Week Range

ARTIVION, INC. (AORT) currently trades at $37.63. The stock gained $1.12 (3.1%) in the most recent trading session. The 52-week high for AORT is $48.25, which means the stock is currently trading -22.0% from its annual peak. The 52-week low is $21.97, putting the stock 71.3% above its annual trough. Recent trading volume was 448K shares, suggesting relatively thin trading activity.

Is AORT Overvalued or Undervalued? — Valuation Analysis

ARTIVION, INC. (AORT) carries a value factor score of 45/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 337.96x, compared to the Healthcare sector average of 23.63x — a premium of 1330%. The price-to-book ratio stands at 3.81x, versus the sector average of 2.75x. The price-to-sales ratio is 4.06x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, AORT trades at 70.05x EV/EBITDA, versus 6.34x for the sector.

Overall, AORT's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

ARTIVION, INC. Profitability — ROE, Margins, and Quality Score

ARTIVION, INC. (AORT) earns a quality factor score of 49/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 1.1%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at 0.6% versus the sector average of -33.1%.

On a margin basis, ARTIVION, INC. reports gross margins of 64.6%, compared to 71.5% for the sector. The operating margin is 6.3% (sector: -66.1%). Net profit margin stands at 1.0%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 15.7% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

AORT Debt, Balance Sheet, and Financial Health

ARTIVION, INC. has a debt-to-equity ratio of 48.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 3.53x, indicating strong short-term liquidity. Total debt on the balance sheet is $215M. Cash and equivalents stand at $73M.

AORT has a beta of 0.66, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for ARTIVION, INC. is 63/100, reflecting average volatility within the normal range for its sector.

ARTIVION, INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, ARTIVION, INC. reported revenue of $421M and earnings per share (EPS) of $0.22. Net income for the quarter was $5M. Gross margin was 64.6%. Operating income came in at $27M.

In FY 2025, ARTIVION, INC. reported revenue of $441M and earnings per share (EPS) of $0.22. Net income for the quarter was $10M. Gross margin was 64.4%. Revenue grew 13.6% year-over-year compared to FY 2024. Operating income came in at $34M.

In Q3 2025, ARTIVION, INC. reported revenue of $113M and earnings per share (EPS) of $0.14. Net income for the quarter was $7M. Gross margin was 65.6%. Revenue grew 18.4% year-over-year compared to Q3 2024. Operating income came in at $13M.

In Q2 2025, ARTIVION, INC. reported revenue of $113M and earnings per share (EPS) of $0.03. Net income for the quarter was $1M. Gross margin was 64.7%. Revenue grew 15.3% year-over-year compared to Q2 2024. Operating income came in at $8M.

Over the past 8 quarters, ARTIVION, INC. has demonstrated a growth trajectory, with revenue expanding from $98M to $421M. Investors analyzing AORT stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

AORT Dividend Yield and Income Analysis

ARTIVION, INC. (AORT) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

AORT Momentum and Technical Analysis Profile

ARTIVION, INC. (AORT) has a momentum factor score of 47/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 27/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 15/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

AORT vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, ARTIVION, INC. (AORT) ranks #189 out of 838 stocks based on the Blank Capital composite score. This places AORT in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing AORT against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full AORT vs S&P 500 (SPY) comparison to assess how ARTIVION, INC. stacks up against the broader market across all factor dimensions.

AORT Next Earnings Date

No upcoming earnings date has been announced for ARTIVION, INC. (AORT) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy AORT? — Investment Thesis Summary

ARTIVION, INC. presents a balanced picture with arguments on both sides. Low volatility (stability score 63/100) reduces downside risk.

In summary, ARTIVION, INC. (AORT) earns a Hold rating with a composite score of 43.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on AORT stock.

Related Resources for AORT Investors

Explore more research and tools: AORT vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare AORT head-to-head with peers: AORT vs AZN, AORT vs SLGL, AORT vs VMD.